$WELNF
Integrated Wellness Acquisition Corp

2022 Q4 Form 10-K Financial Statement

#000141057823000583 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $380.0K $1.052M
YoY Change 226.14% 802.66%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $400.4K $1.124M
YoY Change 183.4% 670.28%
Operating Profit -$1.124M
YoY Change
Interest Expense $1.210M $1.692M
YoY Change 335994.44% 469875.0%
% of Operating Profit
Other Income/Expense, Net $1.692M
YoY Change
Pretax Income $809.5K $567.5K
YoY Change -674.41% -489.77%
Income Tax
% Of Pretax Income
Net Earnings $809.5K $567.5K
YoY Change -674.41% -489.77%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.06 $0.04
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $437.0K $437.0K
YoY Change -75.18% -75.18%
Cash & Equivalents $437.0K
Short-Term Investments
Other Short-Term Assets $365.6K $365.6K
YoY Change 2281.43% 2281.43%
Inventory
Prepaid Expenses $365.5K
Receivables
Other Receivables
Total Short-Term Assets $802.5K $802.5K
YoY Change -54.82% -54.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $119.0M $119.0M
YoY Change 1.44% 1.44%
Total Long-Term Assets $119.0M $119.0M
YoY Change 1.44% 1.44%
TOTAL ASSETS
Total Short-Term Assets $802.5K $802.5K
Total Long-Term Assets $119.0M $119.0M
Total Assets $119.8M $119.8M
YoY Change 0.6% 0.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $56.65K $56.65K
YoY Change 4.14% 4.14%
Accrued Expenses $212.8K $212.8K
YoY Change 473.54% 136.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $294.9K $294.9K
YoY Change 104.42% 104.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.025M $4.025M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $4.025M $4.025M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $294.9K $294.9K
Total Long-Term Liabilities $4.025M $4.025M
Total Liabilities $4.320M $4.320M
YoY Change 3.61% 3.61%
SHAREHOLDERS EQUITY
Retained Earnings -$3.518M
YoY Change 46.98%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.517M $115.5M
YoY Change
Total Liabilities & Shareholders Equity $119.8M $119.8M
YoY Change 0.6% 0.6%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $809.5K $567.5K
YoY Change -674.41% -489.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $1.192M -$37.26K
YoY Change -2887.75% -46.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.312M -$1.312M
YoY Change -98.88% -98.88%
Cash From Investing Activities -$1.312M -$1.312M
YoY Change -98.88% -98.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.50K 25.50K
YoY Change -99.98% -99.98%
NET CHANGE
Cash From Operating Activities 1.192M -37.26K
Cash From Investing Activities -1.312M -1.312M
Cash From Financing Activities 25.50K 25.50K
Net Change In Cash -94.61K -1.324M
YoY Change -105.37% -175.18%
FREE CASH FLOW
Cash From Operating Activities $1.192M -$37.26K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10921
CY2022 dei City Area Code
CityAreaCode
845
CY2022 dei Local Phone Number
LocalPhoneNumber
651-5039
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001877557
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Liabilities
Liabilities
4169283
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41131
CY2022 dei Entity Registrant Name
EntityRegistrantName
INTEGRATED WELLNESS ACQUISITION CORP
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1615488
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
148 N Main Street Florida
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Florida
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
114655000
CY2022 dei Auditor Firm
AuditorFirmId
243
CY2022 dei Auditor Name
AuditorName
BDO USA, LLP
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436972
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1760884
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
365545
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15350
CY2022Q4 us-gaap Assets Current
AssetsCurrent
802517
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1776234
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
118992274
CY2021Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
117300361
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
118992274
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
117300361
CY2022Q4 us-gaap Assets
Assets
119794791
CY2021Q4 us-gaap Assets
Assets
119076595
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
212784
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37100
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
56654
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
54400
CY2021Q4 wel Accrued Offering Costs
AccruedOfferingCosts
52783
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
25500
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
294938
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
144283
CY2022Q4 wel Deferred Underwriter Fee
DeferredUnderwriterFee
4025000
CY2021Q4 wel Deferred Underwriter Fee
DeferredUnderwriterFee
4025000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4025000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4025000
CY2022Q4 us-gaap Liabilities
Liabilities
4319938
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3517709
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2393337
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3517421
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2393049
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119794791
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119076595
CY2022 wel Formation And Operating Costs
FormationAndOperatingCosts
72777
wel Formation And Operating Costs
FormationAndOperatingCosts
29471
CY2022 wel Accounting And Legal Expenses
AccountingAndLegalExpenses
397266
wel Accounting And Legal Expenses
AccountingAndLegalExpenses
86660
CY2022 wel Listing Fee
ListingFee
175357
CY2022 wel Insurance Expense
InsuranceExpense
463980
wel Insurance Expense
InsuranceExpense
27440
CY2022 wel Advertising And Marketing Expense
AdvertisingAndMarketingExpense
12233
wel Advertising And Marketing Expense
AdvertisingAndMarketingExpense
2400
CY2022 wel Administrative Expenses
AdministrativeExpenses
2759
CY2022 us-gaap Operating Expenses
OperatingExpenses
1124372
us-gaap Operating Expenses
OperatingExpenses
145971
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1124372
us-gaap Operating Income Loss
OperatingIncomeLoss
-145971
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1312150
us-gaap Investment Income Interest
InvestmentIncomeInterest
262
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
379763
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
99
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1691913
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
361
CY2022 us-gaap Net Income Loss
NetIncomeLoss
567541
us-gaap Net Income Loss
NetIncomeLoss
-145610
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2393049
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1691913
CY2022 us-gaap Net Income Loss
NetIncomeLoss
567541
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3517421
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4799854
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
6850000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
13922293
us-gaap Net Income Loss
NetIncomeLoss
-145610
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2393049
CY2022 us-gaap Net Income Loss
NetIncomeLoss
567541
us-gaap Net Income Loss
NetIncomeLoss
-145610
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
379763
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
99
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
350195
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
15350
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
177938
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
91500
CY2022 wel Inceasedecreaseinaccruedofferingcosts
Inceasedecreaseinaccruedofferingcosts
-52783
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37262
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69559
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
117300000
CY2022 wel Proceeds From Reinvestment Of Dividends Received From Interest On Trust Account
ProceedsFromReinvestmentOfDividendsReceivedFromInterestOnTrustAccount
-1312150
wel Proceeds From Reinvestment Of Dividends Received From Interest On Trust Account
ProceedsFromReinvestmentOfDividendsReceivedFromInterestOnTrustAccount
-262
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1312150
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-117300262
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
115000000
wel Payment Of Underwriting Expense For Stock Issuance
PaymentOfUnderwritingExpenseForStockIssuance
2300000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6850000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
228080
wel Paymentofdeferredofferingcosts
Paymentofdeferredofferingcosts
191215
CY2022 wel Payment Made By Sponsor On Behalf Of Company
PaymentMadeBySponsorOnBehalfOfCompany
25500
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25500
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119130705
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1323912
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1760884
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1760884
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436972
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1760884
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1691913
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
13922293
wel Deferred Underwriters Fee Liability
DeferredUnderwritersFeeLiability
4025000
wel Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
52783
us-gaap Stock Issued1
StockIssued1
228080
CY2022 wel Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2022 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2300000
CY2022 wel Underwriting Discount
UnderwritingDiscount
4025000
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
497078
CY2022 wel Thres Hold Minimum Aggregate Fair Market Value As Percentage Of Net Assets Held In Trust Account
ThresHoldMinimumAggregateFairMarketValueAsPercentageOfNetAssetsHeldInTrustAccount
0.80
CY2022Q4 wel Minimum Net Tangible Assets Upon Consummations Of Business Combination
MinimumNetTangibleAssetsUponConsummationsOfBusinessCombination
5000001
CY2022 wel Threshold Percentage Of Public Shares Subject To Redemption Without Company Prior Written Consent
ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanyPriorWrittenConsent
0.15
CY2022 wel Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2022 wel Threshold Period From The Closing Of The Public Offering To Consummate A Business Combination As Per Amended And Restated Memorandum And Articles Of Association
ThresholdPeriodFromTheClosingOfThePublicOfferingToConsummateABusinessCombinationAsPerAmendedAndRestatedMemorandumAndArticlesOfAssociation
P18M
CY2022 wel Threshold Period From The Closing Of The Public Offering Extends The Period Of Time To Consummate A Business Combination
ThresholdPeriodFromTheClosingOfThePublicOfferingExtendsThePeriodOfTimeToConsummateABusinessCombination
P21M
CY2022 wel Payments To Acquire Restricted Investment For Each Additional Three Month Period
PaymentsToAcquireRestrictedInvestmentForEachAdditionalThreeMonthPeriod
2300000
CY2022Q4 wel Payments To Acquire Restricted Investment For Each Additional Three Month Period Per Share
PaymentsToAcquireRestrictedInvestmentForEachAdditionalThreeMonthPeriodPerShare
0.20
CY2022 wel Maximum Net Interests To Pay Dissolution Expenses
MaximumNetInterestsToPayDissolutionExpenses
100000
CY2022Q4 wel Minimum Per Share Amount To Be Maintained In The Trust Account
MinimumPerShareAmountToBeMaintainedInTheTrustAccount
10.20
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436972
CY2022Q4 wel Working Capital
WorkingCapital
507579
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 8pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 8pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 7.95pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 wel Transaction Costs Of Ipo
TransactionCostsOfIpo
6822078
CY2021Q4 wel Underwriting Discount
UnderwritingDiscount
2300000
CY2021Q4 wel Deferred Underwriting Discount
DeferredUnderwritingDiscount
4025000
CY2021Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
497078
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
567541
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1691913
CY2022 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-1124372
us-gaap Net Income Loss
NetIncomeLoss
-6671
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-138939
us-gaap Net Income Loss
NetIncomeLoss
-145610
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
13922293
us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-14067903
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 7.95pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 7.95pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed Federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. At December 31, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2022 wel Disclosure Of Private Placement
DisclosureOfPrivatePlacement
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 4 — PRIVATE PLACEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 8pt;">Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 6,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant ($6,850,000 in the aggregate). Each Private Placement Warrant is exercisable for one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 6). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants will expire worthless.</p>
CY2021Q4 wel Working Capital Loans Outstanding
WorkingCapitalLoansOutstanding
0
CY2022Q4 wel Working Capital Loans Outstanding
WorkingCapitalLoansOutstanding
0
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
118992274
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
117300361

Files In Submission

Name View Source Status
0001410578-23-000583-index-headers.html Edgar Link pending
0001410578-23-000583-index.html Edgar Link pending
0001410578-23-000583.txt Edgar Link pending
0001410578-23-000583-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wel-20221231.xsd Edgar Link pending
wel-20221231x10k.htm Edgar Link pending
wel-20221231xex31d1.htm Edgar Link pending
wel-20221231xex31d2.htm Edgar Link pending
wel-20221231xex32d1.htm Edgar Link pending
wel-20221231xex32d2.htm Edgar Link pending
wel-20221231_def.xml Edgar Link unprocessable
wel-20221231_cal.xml Edgar Link unprocessable
wel-20221231_lab.xml Edgar Link unprocessable
wel-20221231_pre.xml Edgar Link unprocessable
wel-20221231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable